Prof. Dr. Hans-Christoph Becker from Stanford University, a long-standing user of mint Lesion™, shares his experience of using the software in this brief interview. He talks about the reaction he…
GoTo
In a retrospective study [1], a team from Royal Marsden in London and Sutton explored changes of CT texture analysis metrics in unresectable liver metastases in patients with colorectal cancer (CRC)…
GoTo
From my initial experience with mint Lesion™ software, and over the time I have been using it, I have been pleased with the software and come to depend on it. Assessing tumor response to therapy…
GoTo
Funded by the National Institute of Health Research (NIHR) and sponsored by the Imperial College London, the MROC study boasts impressive figures: 645 women with suspected or confirmed ovarian cancer…
GoTo
Since the beginning of 2017, all PI-RADS v2 reads are exclusively performed with mint Lesion™ by PD Dr. Matthias Röthke, Chief Medical Officer at Conradia in Hamburg. In this interview, he…
GoTo
The University Hospital in Innsbruck, Austria, has been using mint Lesion™ since mid-2015 with the initial focus on clinical trials in order to guarantee the conformity with the guidelines defined in…
GoTo
Since the end of 2011, mint Lesion™ has been in use at the University Hospital in Basel, Switzerland, – initially merely as a tool for clinical trials, but now also as the standard instrument for the…
GoTo
Distinguishing between enchondroma, a benign tumor, and low-grade chondrosarcoma, which is a low-aggressivity malignancy, is a frequent challenge, as the lesions are both histologically and…
GoTo